According to Tekmira, AlCana is an “instrument of Alnylam” used to “escape the licensing and royalty obligations” of the companies' agreements.
"Tekmira will be responsible for preparing the SNALP formulations and Pfizer will evaluate the formulations in preclinical models," the companies said.
In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.
After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.
Canada begins its search for a chief government science advisor, Nature News reports.
A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.